Spero Therapeutics (SPRO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SPRO Spero Therapeutics

Watchlist

1.280
-0.005-0.39%

Close Oct 18 16:00 ET

1.309
+0.029+2.26%

Post 17:01 ET

69.18MMarket Cap3.76P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Spero Therapeutics Presents In Vitro Data At IDWeek 2024 Showing SPR719 Has Low Propensity For Resistance Development In NTM-PD MAC Strains, Highlighting SPR720's Potential For Prolonged Combination Regimens
BenzingaOct 16 16:08 ET
Promising Clinical Developments Underpin Buy Rating for Spero Therapeutics
TipRanksOct 3 06:17 ET · Ratings
Spero Therapeutics Phase 1 Trial of Lung Disease Treatment Backs Further Assessment
MT NewswiresOct 2 16:58 ET
Spero Therapeutics Announces Publication of SPR719 Trial Data
TipRanksOct 2 16:35 ET
Spero Therapeutics Shares Are Trading Higher After the Company Announced the Publication of Data From Its Phase 1 Clinical Trial, Which Assessed the Intrapulmonary Pharmacokinetics of SPR719.
BenzingaOct 2 16:31 ET
Express News | Spero Therapeutics Publishes SPR720 Phase 1 Lung Exposure Data In Antimicrobial Agents And Chemotherapy
BenzingaOct 2 16:30 ET

Comments

Jaguar8

Oct 16 15:06

NEWS

$Spero Therapeutics (SPRO.US)$
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
Spero Therapeutics announced a poster presentation at IDWeek 2024 showcasing in vitro data on SPR719, the active moiety of SPR720, for treating nontuberculous mycobacterium pulmonary disease (NTM-PD). The study, conducted with Microbiologics, revealed:
1. SPR719's low propensity for resistance d...

Jaguar8

Oct 2 15:31

NEWS

$Spero Therapeutics (SPRO.US)$
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
Spero Therapeutics (Nasdaq: SPRO) has published data from its Phase 1 clinical trial assessing the intrapulmonary pharmacokinetics of SPR719, the active moiety of SPR720, in Antimicrobial Agents and Chemotherapy. The study, involving 33 healthy subjects, showed significant lung uptake and enhanced concentrations of SPR719 in epithelial lining fl...

Tonyco

Sep 30 13:39

$Metagenomi Technologies, LLC (MGX.US)$ $Lantronix (LTRX.US)$
$Fate Therapeutics (FATE.US)$
$Navitas Semiconductor (NVTS.US)$
Opened up some positions on these today.
Increased $Rivian Automotive (RIVN.US)$ , $X4 Pharmaceuticals (XFOR.US)$
Took profit on $FTC Solar (FTCI.US)$ , $GigaCloud Technology (GCT.US)$ and $Aurora Innovation (AUR.US)$
I'll be back in GCT and AUR for sure.
Still looking at $Spero Therapeutics (SPRO.US)$ and $Acacia Research (ACTG.US)$ too.
Exciting day for dips!

Tonyco

Sep 21 23:12

$Spero Therapeutics (SPRO.US)$
Gonna be looking for under 1.3 to hop on. However, 9 days until their P2 trial concludes. If momentum builds, it may push it really high before then plummet after. Or, as I am hoping, it sinks until the news drops and gets a temp boost.
Right now, it looks likely to drop due to the MACD death cross.. we shall see

BadPaint

May 2 08:55

$Sunshine Biopharma (SBFM.US)$ got 595 at .8213, i know its a low hold (i got a cannon aimed at $Spero Therapeutics (SPRO.US)$ at the moment. but damn! lets go!

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

SPRO Spero Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target